RxDoctor Payments Data

Ross Wickstrom

Family · Wilmington, OHNPI 1003265364

Payments from drug & device makers

$634in general payments, 2019–2025

Across 25 payments — averaging $25.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$164
  • Lilly USA, LLC$154
  • AbbVie$85
  • Novo Nordisk$57
  • Astellas Pharma US Inc$25
  • Exact Sciences$24
  • plus $125 from 7 others

What the payments were for

  • Food & beverage$62398%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$634 in reported general payments places this provider in the 60th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$80,840
Medicare patients
177
Services billed
1,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide112$145,134
EliquisApixaban113$104,683
TrulicityDulaglutide51$65,027
FarxigaDapagliflozin Propanediol57$53,406
XareltoRivaroxaban50$47,334
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog39$45,675
JardianceEmpagliflozin53$39,689
MounjaroTirzepatide35$35,152
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$29,518
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog39$27,429
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$26,590
JanuviaSitagliptin Phosphate19$25,859
Tresiba Flextouch U-200Insulin Degludec18$22,480
Tresiba Flextouch U-100Insulin Degludec26$19,363
Repatha SureclickEvolocumab28$17,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$57$145,134112 claims
PfizerEliquis$15$104,683113 claims
Lilly USA, LLCTrulicity, Mounjaro$154$100,17986 claims
AstraZenecaFarxiga, Breztri Aerosphere$164$79,99581 claims
GSKTrelegy Ellipta$16$29,51835 claims
Astellas Pharma US IncMyrbetriq$25$13,94822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,812 family providers in Ohio.

Other family in Wilmington

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →